User-life of ICS/LABA inhaler devices should be considered when prescribed as relievers

Eur Respir J. 2021 Jan 14;57(1):2003921. doi: 10.1183/13993003.03921-2020. Print 2021 Jan.

Roy A Pleasants¹, Stephen L Tilley², Anthony J Hickey^{3

4}, Omar S Usmani⁵

¹ University of North Carolina at Chapel Hill, Division of Pulmonary Diseases and Critical Care Medicine, Chapel Hill, NC, USA [email protected].
² University of North Carolina at Chapel Hill, Division of Pulmonary Diseases and Critical Care Medicine, Chapel Hill, NC, USA.
³ RTI International, Engineered Systems, Research Triangle Park, NC, USA.
⁴ University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, NC, USA.
⁵ Imperial College London and Royal Brompton Hospital, National Heart and Lung Institute, London, UK.

No abstract available

Publication types